Pretax income is the income that a company earns before paying income taxes. Entera Bio's pretax income for the
three
months ended in Dec. 2023 was $-2.00 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.86 Mil.
Entera Bio's pretax margin was %.
During the past 9 years, Entera Bio's highest Pretax Margin was -2060.80%. The lowest was -9652.24%. And the median was -3067.40%.
Entera Bio Pre-Tax Income Historical Data
The historical data trend for Entera Bio's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Entera Bio's Pre-Tax Income
For the Biotechnology subindustry, Entera Bio's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Entera Bio's Pre-Tax Income falls into.
Entera Bio Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Entera Bio's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (NAS:ENTX) Pre-Tax Income Explanation
Entera Bio's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 9 years, Entera Bio's highest Pretax Margin was -2060.80%. The lowest was -9652.24%. And the median was -3067.40%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Entera Bio's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENTX has been successfully added to your 